Drugs & Therapy Perspectives

, Volume 20, Issue 9, pp 1–4 | Cite as

Inhaled tobramycin improves lung function and bacterial density associated with Pseudomonas aeruginosa infections in patients with cystic fibrosis

Drugs and Profile Reports
  • 34 Downloads

References

  1. 1.
    Lamb HM, Goa KL. Management of patients with cystic fibrosis: defining the role of inhaled tobramycin. Dis Manage Health Outcomes 1999; 6(2): 93–108CrossRefGoogle Scholar
  2. 2.
    Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®): a review of its use in the management of pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003; 63(22): 2501–20PubMedCrossRefGoogle Scholar
  3. 3.
    CHIRON Corporation. TOBI Prescribing Information. Emeryville (CA): CHIRON Corporation, 2001Google Scholar
  4. 4.
    Rosenfeld M, Cohen M, Ramsey B. Aerosolized antibiotics for bacterial lower airway infections: principles, efficacy, and pitfalls. Infect Dis Clin Pract 1998 Feb; 7(2): 66–79CrossRefGoogle Scholar
  5. 5.
    Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999 Jan 7; 340(1): 23–30PubMedCrossRefGoogle Scholar
  6. 6.
    Ramsey BW, Schaeffler B, Montgomery AB, et al. Survival and lung function during 2 years treatment with intermittent inhaled tobramycin in CF patients [abstract no. 237]. Neth J Med 1998; 54 Suppl. : S83–4CrossRefGoogle Scholar
  7. 7.
    Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002 Sep; 20(3): 658–64PubMedCrossRefGoogle Scholar
  8. 8.
    Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999 May; 179(5): 1190–6PubMedCrossRefGoogle Scholar
  9. 9.
    lies R, Legh-Smith J, Prevost T, et al. Economic evaluation of tobramycin nebuliser solution in cystic fibrosis. J Cystic Fibrosis 2003; 2: 120–8CrossRefGoogle Scholar
  10. 10.
    Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003 Mar; 167(6): 841–9PubMedCrossRefGoogle Scholar
  11. 11.
    British National Formulary. No. 47. London: The Pharmaceutical Press, Mar 2004Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations